FDA Breakthrough Device Designation for JointMedica's Polymotion® Hip Resurfacing System

17 May 2022

FDA Breakthrough Device Designation for JointMedica's Polymotion® Hip Resurfacing System

Terry Smith, Managing Director said " This designation by the FDA is a validation of our core belief at JointMedica — that our hip resurfacing device addresses an acute unmet need of relatively younger, active hip arthritis patients"

We would like to give special thanks to our friends at MCRA for assisting us with this process.

Click here for the full press release.